Beta Bionics Inc
NASDAQ:BBNX
Net Margin
Beta Bionics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
B
|
Beta Bionics Inc
NASDAQ:BBNX
|
689.6m USD |
-84%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
230.4B USD |
32%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
183.9B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
151.4B USD |
12%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
144.6B USD |
12%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
110.1B USD |
14%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
52.2B EUR |
9%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
48.6B USD |
7%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
44.1B USD |
75%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
42.3B USD |
23%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
273.8B CNY |
31%
|
Beta Bionics Inc
Glance View
Beta Bionics, Inc. is a commercial-stage medical device company. The company is headquartered in Irvine, California and currently employs 279 full-time employees. The company went IPO on 2025-01-30. The firm's product, the iLet Bionic Pancreas (iLet), is an insulin delivery device cleared by the United States Food and Drug Administration (FDA) to utilize adaptive closed-loop algorithms to autonomously determine every insulin dose without requiring a user to count carbohydrate intake. iLet is used for the treatment of Type 1 diabetes (T1D). The firm's solutions include iLet for Adults, iLet for Children, Bionic Circle App and iLet Simulator. The firm is in the early stages of developing an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing, commonly known in the diabetes industry as a patch pump. The company is also in the early stages of developing a bihormonal configuration of the iLet.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Beta Bionics Inc's most recent financial statements, the company has Net Margin of -84.1%.
You don't have any saved screeners yet